Placental Site Trophoblastic Tumors and Epithelioid Trophoblastic Tumors.

Epithelioid trophoblastic tumor Gestational trophoblastic neoplasia Placental site trophoblastic tumor

Journal

Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473

Informations de publication

Date de publication:
24 Sep 2024
Historique:
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 25 9 2024
Statut: aheadofprint

Résumé

Placental site trophoblastic disease (PSTT) and epithelioid trophoblastic tumor (ETT) are the rarest forms of gestational trophoblastic neoplasia (GTN) with unique clinical features and treatment considerations. Unlike other GTN, human chorionic gonadotropin (hCG) is minimally, if at all, elevated. Additionally, unlike other GTN, WHO risk scores are not applied to PSTT/ETT. Management of PSTT/ETT is predominately surgical with hysterectomy and possible lymphadenectomy. There are case reports of fertility sparing surgery for uterine confined disease. Multi-agent chemotherapy ± pembrolizumab is added for those with high risk features defined as advanced stage disease and those diagnosed ≥48 months from the antecedent pregnancy. Survival for early stage, low risk disease remains quite good but the prognosis for high-risk disease is poor and an scenario for which novel treatments are needed.

Identifiants

pubmed: 39322463
pii: S0889-8588(24)00110-2
doi: 10.1016/j.hoc.2024.08.016
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors have nothing to disclose

Auteurs

Victoria Wang (V)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA. Electronic address: Vwang0@bwh.harvard.edu.

Kevin M Elias (KM)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA.

Ross S Berkowitz (RS)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA.

Neil S Horowitz (NS)

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA; New England Trophoblastic Disease Center, Dana-Farber Cancer Institute, MA, USA.

Classifications MeSH